Journal of Lipid Research, Vol 30, 1591-1600, Copyright © 1989 by Lipid Research, Inc.

ARTICLES

Effects of lovastatin therapy on guinea pig low density lipoprotein composition and metabolism

L Berglund, MF Sharkey, RL Elam and JL Witztum
Department of Medicine, University of California, San Diego, La Jolla 92093-0613.

Lovastatin therapy is known to induce hepatic low density lipoprotein (LDL) receptor mRNA and LDL receptor activity. Yet, in studies in humans and animals it has been difficult to demonstrate an enhancement of the plasma fractional catabolic rate (FCR) of an injected LDL tracer during lovastatin therapy. One explanation may be that the composition of the LDL tracer may also change during therapy, independently affecting LDL clearance. To test this possibility we fed guinea pigs lovastatin, which led to a decrease in their plasma LDL cholesterol levels. Composition studies showed that LDL isolated from lovastatin- treated guinea pigs was slightly cholesterol-depleted and triglyceride- enriched when compared to LDL isolated from control animals. Several independent lines of investigation documented that a substantial increase in hepatic LDL receptor activity occurred in response to the lovastatin treatment. Consistent with this, when a single LDL tracer was injected into control and lovastatin-treated guinea pigs, the FCR was always more rapid in the lovastatin-treated animals. However, when LDL isolated from lovastatin-treated animals (L-LDL) was simultaneously injected intravenously with LDL isolated from control animals (C-LDL) the FCR of the C-LDL was always more rapid than that of the L-LDL. When one compared the FCR of C-LDL determined in control animals with the FCR of L-LDL determined in lovastatin animals there was no difference. Possible explanations for these paradoxical findings are discussed.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Berglund Lipoprotein Metabolism: A Well-Tried Tool to Characterize Dyslipidemic Mechanisms. Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1201 - 1203. [Full Text] [PDF]

				D. E. Telford, J. Y. Edwards, S. M. Lipson, B. Sutherland, P. H. R. Barrett, J. R. Burnett, E. S. Krul, B. T. Keller, and M. W. Huff Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB J. Lipid Res., May 1, 2003; 44(5): 943 - 952. [Abstract] [Full Text] [PDF]

				M. L. Fernandez Guinea Pigs as Models for Cholesterol and Lipoprotein Metabolism J. Nutr., January 1, 2001; 131(1): 10 - 20. [Abstract] [Full Text]

				S. Roy, S. Vega-Lopez, and M. L. Fernandez Gender and Hormonal Status Affect the Hypolipidemic Mechanisms of Dietary Soluble Fiber in Guinea Pigs J. Nutr., March 1, 2000; 130(3): 600 - 607. [Abstract] [Full Text]

				M. Vergara-Jimenez, K. Conde, S. K. Erickson, and M. L. Fernandez Hypolipidemic mechanisms of pectin and psyllium in guinea pigs fed high fat–sucrose diets: alterations on hepatic cholesterol metabolism J. Lipid Res., July 1, 1998; 39(7): 1455 - 1465. [Abstract] [Full Text]

				L. Berglund, J. L. Witztum, N. F. Galeano, A. S. Khouw, H. N. Ginsberg, and R. Ramakrishnan Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach J. Lipid Res., April 1, 1998; 39(4): 913 - 924. [Abstract] [Full Text]

				J. R. Burnett, L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2589 - 2600. [Abstract] [Full Text]

				M. Tilly-Kiesi, S. P. Mattila, and M. J. Tikkanen Effects of Lovastatin on High-Density Lipoprotein Subfractions in Hypercholesterolemic Patients with Peripheral Vascular Disease Angiology, February 1, 1993; 44(2): 129 - 137. [Abstract] [PDF]